Free Trial

Immuneering (IMRX) Competitors

Immuneering logo
$8.49 +0.28 (+3.41%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$8.41 -0.08 (-0.94%)
As of 06:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IMRX vs. KALV, AKBA, DAWN, TNGX, IMTX, NRIX, OCS, NAGE, VALN, and GYRE

Should you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include KalVista Pharmaceuticals (KALV), Akebia Therapeutics (AKBA), Day One Biopharmaceuticals (DAWN), Tango Therapeutics (TNGX), Immatics (IMTX), Nurix Therapeutics (NRIX), Oculis (OCS), Niagen Bioscience (NAGE), Valneva (VALN), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry.

Immuneering vs. Its Competitors

Immuneering (NASDAQ:IMRX) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

Immuneering's return on equity of -146.28% beat KalVista Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuneeringN/A -146.28% -117.22%
KalVista Pharmaceuticals N/A -195.62%-89.96%

Immuneering has higher revenue and earnings than KalVista Pharmaceuticals. Immuneering is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immuneering$320K1,102.90-$61.04M-$1.89-4.49
KalVista PharmaceuticalsN/AN/A-$183.44M-$3.94-3.56

67.7% of Immuneering shares are owned by institutional investors. 22.9% of Immuneering shares are owned by company insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, KalVista Pharmaceuticals had 23 more articles in the media than Immuneering. MarketBeat recorded 27 mentions for KalVista Pharmaceuticals and 4 mentions for Immuneering. Immuneering's average media sentiment score of 0.70 beat KalVista Pharmaceuticals' score of 0.53 indicating that Immuneering is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immuneering
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
KalVista Pharmaceuticals
10 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Immuneering has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of -0.1, meaning that its share price is 110% less volatile than the S&P 500.

Immuneering currently has a consensus target price of $13.00, indicating a potential upside of 53.12%. KalVista Pharmaceuticals has a consensus target price of $26.43, indicating a potential upside of 88.64%. Given KalVista Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Immuneering.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immuneering
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
KalVista Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11

Summary

Immuneering beats KalVista Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Immuneering News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMRX vs. The Competition

MetricImmuneeringMED IndustryMedical SectorNASDAQ Exchange
Market Cap$352.93M$3.15B$5.78B$10.18B
Dividend YieldN/A2.32%5.73%4.60%
P/E Ratio-4.4921.5775.3926.02
Price / Sales1,102.90254.90460.5891.38
Price / CashN/A44.4425.8129.91
Price / Book6.389.6112.836.25
Net Income-$61.04M-$53.29M$3.29B$270.76M
7 Day Performance42.69%0.57%0.85%2.54%
1 Month Performance125.80%4.56%4.68%5.73%
1 Year Performance320.30%10.44%70.14%25.85%

Immuneering Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMRX
Immuneering
3.4332 of 5 stars
$8.49
+3.4%
$13.00
+53.1%
+320.3%$352.93M$320K-4.4960
KALV
KalVista Pharmaceuticals
4.0112 of 5 stars
$15.96
+0.9%
$26.29
+64.7%
+25.8%$796.38MN/A-4.33100Trending News
Earnings Report
Analyst Forecast
AKBA
Akebia Therapeutics
3.7888 of 5 stars
$3.13
+5.7%
$6.75
+115.7%
+102.1%$784.83M$160.18M-18.41430News Coverage
Positive News
Analyst Downgrade
DAWN
Day One Biopharmaceuticals
2.9297 of 5 stars
$7.47
-1.1%
$25.29
+238.5%
-49.6%$773.36M$131.16M-7.8660Positive News
TNGX
Tango Therapeutics
1.9485 of 5 stars
$6.81
-1.9%
$10.50
+54.2%
-37.8%$772.15M$42.07M-5.1290
IMTX
Immatics
2.9154 of 5 stars
$5.81
-7.2%
$14.67
+152.4%
-54.1%$760.90M$168.65M-8.94260Positive News
NRIX
Nurix Therapeutics
2.3721 of 5 stars
$9.70
-2.1%
$29.07
+199.7%
-63.5%$757.61M$54.55M-3.72300Positive News
OCS
Oculis
3.1341 of 5 stars
$17.25
+0.2%
$35.75
+107.2%
+45.7%$751.86MN/A-6.462Analyst Upgrade
Short Interest ↓
NAGE
Niagen Bioscience
2.231 of 5 stars
$9.45
+0.4%
$13.42
+42.0%
N/A$750.47M$99.60M45.00120Positive News
VALN
Valneva
2.7914 of 5 stars
$8.52
-1.5%
$15.00
+76.1%
+40.0%$743.27M$183.52M-8.69700Gap Down
GYRE
Gyre Therapeutics
1.665 of 5 stars
$7.89
+2.6%
$18.00
+128.1%
-42.0%$740.65M$105.76M789.7940Positive News

Related Companies and Tools


This page (NASDAQ:IMRX) was last updated on 9/15/2025 by MarketBeat.com Staff
From Our Partners